Dosage & Administration
For palliative or adjunctive treatment of breast carcinoma: 160 mg or 125 mg/m<sup>2</sup> daily (40 mg q.i.d. or 160 mg q.d.)
For endometrial carcinoma: 80 – 320 mg or 62.5 – 250 mg/m<sup>2</sup> daily in divided doses (40 – 80 mg one to four times daily or one to two 160 mg tablets daily).
For palliative treatment of hormone responsive advanced (Stage D2) carcinoma of the prostate: 120 mg (93.8 mg/m<sup>2</sup>) as a single daily dose in combination with diethylstilbestrol tablet, 0.1 mg.
For anorexia, cachexia, or significant weight loss in patients with cancer: usual adult dose: 400 to 800 mg as a single daily dose.
The recommended adult initial dosage of megestrol acetate oral suspension is 625 mg/day (5 mL/day or one teaspoon daily). Shake container well before using
- Thromboembolic phenomena: Thromboembolic phenomena including thrombophlebitis and pulmonary embolism (in some cases fatal) have been reported.
- Other adverse reactions: Breakthrough uterine bleeding occur in approximately 1% to 2% of patients. Heart failure, cushingoid facies, tumor flare (with or without hypercalcemia), carpal tunnel syndrome and urticaria have been reported.
Pregnancy & Lactation
Nursing mothers: Very small amounts (approximately 0.1%) are excreted in mother’s milk. It is however, not known whether these amounts exert any harmful effect on the newborn. Because of the potential for adverse effects on the new born, nursing should be discontinued during treatment with Megestrol Acetate.
Use in Special Population
Geriatric use: Insufficient data from clinical studies of Megestrol acetate are available for patients 65 years of age and older to determine whether they respond differently than younger patients. In general, dose selection for an elderly patient should be cautious.
Hepatic impairment: Dose selection for a hepatic impaired patient should be cautious.
Renal impairment: Dose selection for a renal impaired patient should be cautious.